Radiation dermatitis is a side effect of external beam ionizing radiation. It is also called radiodermatitis, x-ray dermatitis, radiation skin damage, or a radiation burn. Most commonly, radiation-induced dermatitis is caused by radiotherapy for underlying malignancies.
Radiation Dermatitis Epidemiological Segmentation
The Epidemiological Segmentation of Radiation Dermatitis in 7MM from 2018 to 2030 is segmented into:-
- Radiotherapy Utilization of Radiation Dermatitis
- Incident cases of Radiation Dermatitis
- Grade-specific cases of Radiation Dermatitis
- Treated cases of Radiation Dermatitis
Radiation Dermatitis Epidemiological Insights Observed in 2020
- The total incident population of Radiation Dermatitis in 7MM was found to be 3,012,048.
- The United States had the largest Radiation Dermatitis incident population.
- Among the EU5 countries, Germany had the highest incident cases of Radiation Dermatitis.
- Spain had the lowest Radiation Dermatitis incident cases which were observed to be 151,518.
The Radiation Dermatitis therapeutic market is expected to increase at a CAGR of 14.62% in the 7MM during the study period (2018–2030).
Radiation Dermatitis Market Drivers
- A huge population presents a massive market to any new entrant
- Advances in radiation delivery technology
Radiation Dermatitis Market Barriers
- Radiation leads to decreased quality of life as there is no standard in disease management
- Limited prospective randomized data is available on the use of pharmacologic or supportive care agents, topical or non-topical, to prevent and treat the indication
- The steady rise in alternatives for radiation therapy in the oncology space
- Several off-label treatment options are currently available
The emerging drugs of the Radiation Dermatitis market are
- Tempol (APC-400)
- BMX-001, and others
Radiation Dermatitis Key Players
The key players working in the Radiation Dermatitis market are
- Adamis Pharmaceuticals
- Matrix Biomed
- BioMimetix JV, and others